[Immunotherapeutic reactivity of dendritic cells loaded with a variety of antigen preparations].
The findings summarized here provide a direct comparison of the immunogenicity of various DC loading strategies included pulsing with protein, peptide, tumor cell lysate, irradiated tumor cells and electrofusion of DCs and tumor cells. For the treatment of 3-day established pulmonary metastases, electrofusion of DCs and tumor cells generated a therapeutic vaccine far superior to other methods of DC loading. Consistent with their therapeutic activity, fusion hybrids stimulated the release of the largest amount of interferon-gamma from immune T cells. However, IL-10 secretion did not correlate with in vivo therapeutic reactivity. In conclusion, DC-tumor fusion hybrids were the most effective vaccine to eradicate existing tumors. These data support the use of DC-tumor electrofusion cells for the treatment of human cancer.
Shimizu
Keiji
K
Dept. of Surgery, Division of Digestive Surgery, Kyoto Prefectural University of Medicine.
Kuriyama
Hideyuki
H
Tamai
Hidemasa
H
Ueda
Yuji
Y
Yamagishi
Hisakazu
H
Shu
Suyu
S
D000818:Animals; D000951:Antigens, Neoplasm / Q000276:immunology*; D019496:Cancer Vaccines / Q000276:immunology*; D002459:Cell Fusion / Q000379:methods; D003713:Dendritic Cells / Q000276:immunology*; D005260:Female; D006822:Hybrid Cells / Q000276:immunology; D007371:Interferon-gamma / Q000378:metabolism; D016753:Interleukin-10 / Q000378:metabolism; D008175:Lung Neoplasms / Q000556:secondary / Q000628:therapy*; D008546:Melanoma, Experimental / Q000628:therapy*; D051379:Mice; D008810:Mice, Inbred C57BL; D011674:Pulse; D014611:Vaccination
D000951:Antigens, Neoplasm; D019496:Cancer Vaccines; D016753:Interleukin-10; D007371:Interferon-gamma